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Abstract: The exposure of phosphatidylserine (PtdS) is a common molecular 
marker for both apoptosis and necrosis and enables the simultaneous 
detection of these distinct modes of cell death. Our aim was to develop a 
radiotracer based on the PtdS-binding activity of the C2A domain of 
synaptotagmin I and assess 99mTc-C2A-GST (GST is glutathione S-
transferase) using a reperfused acute myocardial infarction (AMI) rat model. 
Methods: The binding of C2A-GST toward apoptosis and necrosis was 
validated in vitro. After labeling with 99mTc via 2-iminothiolane thiolation, 
radiochemical purity and radiostability were tested. Pharmacokinetics and 
biodistribution were studied in healthy rats. The uptake of 99mTc-C2A-GST 
within the area at risk was quantified by direct γ-counting, whereas 
nonspecific accumulation was estimated using inactivated 99mTc-C2A-GST. In 
vivo planar imaging of AMI in rats was performed on a γ-camera using a 
parallel-hole collimator. Radioactivity uptake was investigated by region-of-
interest analysis, and postmortem tetrazolium staining versus 
autoradiography. Results: Fluorescently labeled and radiolabeled C2A-GST 
bound both apoptotic and necrotic cells. 99mTc-C2A-GST had a radiochemical 
purity of >98% and remained stable. After intravenous injection, the uptake 
in the liver and kidneys was significant. For 99mTc-C2A-GST, radioactivity 
uptake in the area at risk reached between 2.40 and 2.63 %ID/g (%ID/g is 
percentage injected dose per gram) within 30 min and remained plateaued 
for at least 3 h. In comparison, with the inactivated tracer the radioactivity 
reached 1.06 ± 0.49 %ID/g at 30 min, followed by washout to 0.52 ± 
0.23 %ID/g. In 7 of 7 rats, the infarct was clearly identifiable as focal uptake 
in planar images. At 3 h after injection, the infarct-to-lung ratios were 2.48 ± 
0.27, 1.29 ± 0.09, and 1.46 ± 0.04 for acute-infarct rats with 99mTc-C2A-
GST, sham-operated rats with 99mTc-C2A-GST, and acute-infarct rats with 
99mTc-C2A-GST-NHS (NHS is N-hydroxy succinimide), respectively. The 
distribution of radioactivity was confirmed by autoradiography and histology. 
Conclusion: The C2A domain of synaptotagmin I labeled with fluorochromes 
or a radioisotope binds to both apoptotic and necrotic cells. Ex vivo and in 
vivo data indicate that, because of elevated vascular permeability, both 
specific binding and passive leakage contribute to the accumulation of the 
radiotracer in the area at risk. However, the latter component alone is 
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insufficient to achieve detectable target-to-background ratios with in vivo 
planar imaging.  
Keywords: C2A domain, synaptotagmin I, apoptosis, necrosis, myocardial 
infarction 
Noninvasive imaging of cell death has important diagnostic and 
prognostic predictive potentials. Collectively, the underlying pathologic 
cause of many degenerative diseases can be attributed to the interplay 
of different modes of cell death. Among the 2 dominant forms of cell 
death, apoptosis has gained much attention in modern medicine not 
only because of the deleterious consequences of its deregulation but 
also as an opportunity for therapeutic intervention1–5. The active 
process of apoptosis is an intracellular, energy-dependent event6,7. 
Once committed, the execution phase of apoptosis involves a 
proteolytic cascade catalyzed by caspases and is accompanied by 
distinct molecular markers8–11. In contrast, necrosis is a form of 
passive cell death recognized by swelling and plasma membrane 
damage. The characterization of apoptosis and necrosis is likely to 
dictate the development and implementation of novel imaging 
technologies.  
Acute myocardial infarction (AMI) involves both forms of cell 
death, although the exact extent of each remains controversial 
because of variations in animal models and detection methods12. It has 
been generally accepted that necrosis occurs at the central ischemic 
zone, whereas apoptosis is more prevalent in the periphery within the 
area at risk. In addition, apoptotic cell death involves not only 
cardiomyocytes but also nonmyocytes to a comparable degree, 
including vascular endothelium, macrophages, and blood cells13. 
Although conventionally AMI has been regarded as a primarily necrotic 
condition, infarct imaging using necrosis-avid agents has achieved a 
certain degree of success by targeting necrotic markers, such as 
calcium deposit, histone, and myosin epitope14. The better 
understanding of different forms of cell death has presented the 
opportunity to detect multiple, if not all, forms of cell death as a single 
comprehensive category and, thus, has provided the potential 
advantage of being more likely to reflect the true extent of irreversible 
myocardial damage.  
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A common molecular marker for both apoptosis and necrosis is 
the exposure of phosphatidylserine (PtdS), and its presence can 
facilitate target-specific imaging of cell death. In viable cells, PtdS is 
strictly a constituent of the inner leaflet of the plasma membrane. The 
asymmetry of the lipid bilayer is maintained by the actions of energy-
dependent enzymes, including aminophospholipid translocase and 
floppase15. During apoptosis, the inhibition of translocase and floppase 
is accompanied by the activation of scramblase, and the redistribution 
of phospholipids across the bilayers is facilitated15. As a result, PtdS 
becomes exposed onto the cell surface. In necrotic cells, the passive 
rupture of the plasma membrane renders intracellular components, 
including PtdS, accessible to extracellular milieu. As one of the major 
phospholipid components of the plasma membrane, PtdS provides an 
abundant molecular marker for the detection of both apoptosis and 
necrosis once it becomes accessible.  
The C2A domain of synaptotagmin I binds to negatively charged 
phospholipids in membranes, including PtdS, in a calcium-dependent 
manner16. C2A labeled with fluorochromes and contrast agents has 
allowed detection of cell death using fluorescent and MRI techniques, 
respectively17,18. The imaging applications of another protein that binds 
PtdS, annexin V, have also been well documented in a wide range of 
animal models and clinical studies19–22. Meanwhile, derivatives of 
annexin V continue to evolve in the search for improved binding and 
pharmacokinetic profiles23,24.  
The aim of this study was 2-fold: development of a technetium-
based PtdS-binding molecular probe for detecting apoptosis and 
necrosis and characterization of the imaging tracer within the context 
of AMI. To date, the uptake of radiolabeled annexin V in acute and 
chronic infarct has been described in animal models and in human 
patients25,26, but key questions remain unresolved. AMI is 
characterized by a multiplicity of cellular and physiologic changes, not 
only including various forms of cell death but also markedly elevated 
vascular permeability and increased interstitial space27. In fact, these 
structural changes have become the foundation for delineating infarct 
areas with MRI using apparently nonspecific contrast agents27,28. 
Therefore, the presence of PtdS-binding radiotracers in the infarct 
region does not necessarily warrant PtdS interaction but also can be 
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associated with nonspecific leakage of the tracer across the vascular 
boundary and diffusion into the interstitial space. Here, our 
investigation was designed to characterize one such radiotracer, 99mTc-
labeled C2A, for its distribution within the area at risk. The C2A was 
overexpressed and labeled in the form of C2A-GST (GST is glutathione 
S-transferase) fusion protein. The inclusion of GST only moderately 
increases molecular weight but greatly reduces the probability of 
chemical modification in the vicinity of the PtdS-binding site on C2A. 
We show that (a) fluorescently labeled C2A-GST specifically binds to 
both apoptotic and necrotic cells in vitro, (b) the fusion protein can be 
stably labeled with 99mTc at a reasonably high radiochemical yield and 
purity through thiolation using 2-iminothiolane, (c) a high 
accumulation of 99mTc-C2A-GST in the area at risk is attributed to both 
specific binding and passive distribution, and (d) 99mTc-C2A-GST 
uptake allows noninvasive visualization of AMI in a rat model using 
single-photon planar imaging, whereas passive leakage alone was 
insufficient for such detection.  
Materials and Methods 
C2A-GST was overexpressed in Escherichia coli and purified as 
described previously16. The protein was dialyzed in phosphate-buffered 
saline (PBS) (pH 7.4), lyophilized, and stored at −20°C.  
Fluorescein Isothiocyanate (FITC) Labeling of C2A-GST 
and Cell Assays 
Three hundred microliters of C2A-GST (2 mg/mL) in PBS were 
mixed with 2.33 μL of FITC (12 mg/mL in dimethyl sulfoxide [DMSO]) 
and gently shaken for 3 h at room temperature. C2A-GST-FITC was 
purified using a Sephadex G-25 column equilibrated with PBS.  
Apoptosis was induced in Jurkat cells (American Type Culture 
Collection) at a density of 5 × 106 cells/mL with 3.5 μmol/L 
camptothecin (Sigma) for 3 h. C2A-GST-FITC and propidium iodide 
(PI) were added to final concentrations of 1 and 5 μg/mL, respectively. 
The sample was analyzed by 2-color flow cytometry. In parallel, the 
same cells were analyzed with commercial annexin V-FITC (Sigma; 1 
μg/mL) and PI (5 μg/mL) according to the manufacturer's instructions.  
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To test whether both C2A-GST and annexin V recognize the 
same apoptotic or necrotic cells, C2A-GST was labeled with Alexa Fluor 
680 (AF680; Molecular Probes). Specifically, 250 μL of C2A-GST (2 
mg/mL; 100 mmol/L NaHCO3, 60 mmol/L NaCl, pH 8.2) were mixed 
with 12.4 μL of AF680 (1 mg/mL in methanol). After 1 h at room 
temperature while shielded from light, the conjugate was purified 
using G-25 Sephadex chromatography. C2A-GST-AF680 was 
incubated, in the direct presence of annexin V-FITC, with treated 
Jurkat cells and analyzed with flow cytometry to detect C2A-GST–
positive cells (red) and annexin V–positive cells (green).  
99mTc Labeling of C2A-GST  
C2A-GST was labeled with 99mTc in a 2-step process29. 
Specifically, 200 μL of C2A-GST (2 mg/mL) solution in PBS were mixed 
with 2.96 μL of 2-iminothiolane (10 mg/mL in DMSO) and incubated at 
37°C for 1 h. Then 500 μL of in 0.9% NaCl were added to a 
stannous glucoheptonate mixture (80 μg stannous chloride and 8 mg 
sodium glucoheptonate) and incubated at room temperature for 10 
min under N2. Four hundred microliters of 99mTc-glucoheptonate were 
mixed with 200 μL of thiolated C2A-GST and incubated for 30 min at 
room temperature. 99mTc-C2A-GST was purified using Sephadex G-25 
chromatography.  
The radiochemical purity (RCP) of 99mTc-C2A-GST and the 
presence of 99mTc-colloid were analyzed by instant thin-layer 
chromatography (ITLC-SG; Gelman Sciences) using 2 solvent systems 
as the mobile phase: saline and NH3·H2O/alcohol/H2O (1:2:5, v/v/v).  
The stability of 99mTc-C2A-GST was assessed by incubating 
99mTc-C2A-GST (10 μL, 0.2 mg/mL) in 500 μL saline, rat serum, or 
whole blood at room temperature. The RCP was measured by ITLC at 
1, 2, 4, and 24 h with corrections for decay. The degree of thiolation 
was estimated using Ellman's reagent30. For control purposes, inactive 
99mTc-C2A-GST was produced by reacting with 2 mmol/L sulfo-N-
hydroxy succinimide (NHS) acetate for 15 min at room temperature 
and purified.  
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In Vitro Binding Assays 
About 1 μg of 99mTc-C2A-GST was incubated with 500 μL of 
apoptotic or untreated cells (5 × 105) in 15 mmol/L N-(2-
hydroxyethyl) piperazine-N′-(2-ethanesulfonic acid) (HEPES), 120 
mmol/L NaCl, 2 mmol/L CaCl2, pH 7.4. A parallel sample was prepared 
using 99mTc-C2A-GST-NHS as the control. To separate cell-bound from 
free 99mTc-C2A-GST, the mixture was centrifuged at 1,000g for 2 min 
through 100 μL of silicon oil. After removing the aqueous supernatant 
and oil layer, the tip of each tube that contained the pellet was cut off 
and its radioactivity was measured by γ-counting.  
Binding specificity after radiolabeling was evaluated using a 
competition assay. Specifically, 99mTc-C2A-GST (78 nmol/L) was 
incubated with 5 × 105 camptothecin-treated Jurkat cells in the 
presence of unlabeled C2A-GST from 15.9 to 7,830 nmol/L. The 
radioactivity that remained bound to the cells was calculated as a 
percentage of that without competition and plotted against the 
concentration of unlabeled C2A-GST. The 50% inhibitory concentration 
(IC50) at this particular experimental condition was the concentration 
of unlabeled C2A-GST required to reduce the binding of 99mTc-C2A-GST 
by 50% (B50).  
Blood Half-Life and Biodistribution Studies in Normal 
Rats 
Animal procedures were conducted following National Institutes 
of Health guidelines and with institutional approval. Blood clearance of 
99mTc-C2A-GST or 99mTc-C2A-GST-NHS was studied in anesthetized 
healthy male Sprague–Dawley rats (8- to 10-wk old; n = 5). 99mTc-
C2A-GST (46 μg) was injected via a left femoral vein catheter. Ten 
microliters of blood were sampled from a right femoral artery catheter 
at 0.5, 5, 10, 15, 20, 30, 40, 60, 120, and 180 min after injection. The 
blood radioactivity was measured by γ-counting.  
For biodistribution, each rat was injected with 3.7 MBq of 99mTc-
C2A-GST via the femoral vein. One group of 5 rats was sacrificed at 
10, 30, 60, and 180 min after injection. The radioactivity uptake was 
measured for blood, heart, lung, spleen, liver, kidney, stomach, small 
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intestine, large intestine, bone, muscle, fat, and skin by γ-counting 
using an energy window between 120 and 160 keV. Data are 
expressed in terms of percentage injected dose per gram or per organ 
± SD (%ID/g ± SD or %ID/organ ± SD). Blood, muscle, and bone 
were assumed to represent 7%, 40%, and 10% of body weight, 
respectively. The percentages of fat and skin of whole-body weight are 
unavailable and, thus, are not included as %ID/organ.  
Uptake Study in Rat Model of AMI 
This procedure is to quantify the absolute tracer uptake in the 
area at risk versus viable myocardium at different times after 
injection. Here, we used an acute infarct model with 18 min of 
ischemia followed by 2 h of reperfusion. With this model we have 
confirmed the presence of acute infarction using triphenyl tetrazolium 
chloride (TTC) staining. Acute infarct models using a short duration of 
ischemia have also been reported elsewhere28,31.  
For each anesthetized rat, after tracheotomy and intubation, 
respiration was maintained using a rodent respirator. After 
thoracotomy, the left descending coronary artery was ligated for 18 
min using a 6.0 suture at 1 mm below the left atrial appendage. After 
reperfusion, the loose suture was left in place until sacrifice, when an 
area-at-risk measurement was made. 99mTc-C2A-GST (∼7.4 MBq) was 
injected via the femoral vein at 2 h of reperfusion. A group of 4 rats 
was sacrificed at 10, 30, 60, and 180 min after injection. The left 
descending coronary artery was reoccluded at 30 s before sacrifice and 
2 mL of Evans Blue (2% in PBS, w/v) were injected into the femoral 
vein to stain perfused myocardium. The myocardium devoid of Evans 
Blue was considered as the area at risk. After dissecting and weighing 
the heart tissues, tracer uptake in the area at risk and normal 
myocardium was determined separately by γ-counting. The results are 
expressed as %ID/g ± SD. To quantify nonspecific uptake, 99mTc-C2A-
GST-NHS was studied using an identical protocol.  
To investigate whether the uptake of 99mTc-C2A-GST is 
associated with the treatment of ischemia or reperfusion per se, the 
above experiment was repeated with 5 min of ischemia followed by 2 h 
of reperfusion.  
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Histology 
Terminal deoxynucleotidyl transferase–mediated dUTP nick-end 
labeling (TUNEL) was performed according to the manufacturer's 
protocol, using 10-μm short-axis cryosections of the heart. At least 
3,500 nuclei were counted from random fields within the area at risk 
or in the normal region, under a magnification of ×400. The apoptotic 
index was calculated in terms of TUNEL-positive nuclei as a percentage 
of total nuclei. For electron microscopy (EM), specimens from the area 
at risk and the normal myocardium were fixed in 4% 
paraformaldehyde and 0.5% glutaraldehyde for 24 h at 4°C. The 
tissues were dehydrated, sectioned, and mounted on carbon grids for 
transmission EM.  
In Vivo Imaging of AMI in Rat Model 
Reperfused ischemic injury was created in rats as described. To 
examine the background tracer uptake, we included sham-operated 
rats with identical surgery except for coronary occlusion. Either 99mTc-
C2A-GST or 99mTc-C2A-GST-NHS was injected via the femoral vein at a 
dosage of ∼37 MBq, and anterior planar images of each rat in prone 
position were acquired using an Infinia (GE Healthcare) γ-camera and 
parallel-hole collimator with a 15% energy window centering at 140 
keV. A reference radiation source was positioned on the left side of the 
animal. The field of view was 22.5 × 22.5 mm with a 512 × 512 
matrix. Each image was acquired with 1 million counts at 0, 40, 80, 
120, 160, and 200 min after injection. Heart-to-lung ratios were 
estimated using region-of-interest analysis.  
Autoradiography 
After the rat was sacrificed, the heart was harvested and quickly 
rinsed in saline. About 2 mL of 0.5% TTC in HEPES buffer (w/v) was 
infused retrograde into the aorta to stain the entire myocardium. After 
15 min of incubation at 37°C, the heart was fixed in 4% formaldehyde. 
Short-axis sections of the heart with a thickness of ∼500 μm were cut 
and exposed to Kodak BMX MS film overnight at −80°C. After the film 
was developed, each corresponding slice was fixed overnight in 1% 
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formaldehyde in PBS (v/v). Digitized autoradiography and histology 
section images were inspected visually.  
Results 
The fusion protein has a molecular weight of 39,687 Da, with 
346 amino acids, of which 130 are from C2A and 201 are from GST. 
The flexible linker sequence contains 15 residues, in which a thrombin 
cleavage site is included. There are 14 Lys and no Cys in C2A and 19 
Lys and 4 Cys in GST, with the flexible linker peptide containing 
neither residue.  
FITC Labeling of C2A-GST and In Vitro Studies 
The fluorescein-to-protein ratio of C2A-GST-FITC was estimated 
to be 1.1 ± 0.2. To test the binding activity for apoptotic and necrotic 
cells, C2A-GST-FITC was incubated with control or camptothecin-
treated Jurkat cells and analyzed using flow cytometry. As shown in 
Figures 1A and 1B, distinct cell populations were detected as viable 
(V), apoptotic (A), and necrotic (N). In addition, a presumably early 
apoptotic (EA) population was identified with intermediate fluorescent 
intensity. These cells appear to be at a transitional state toward fully 
developed apoptosis or necrosis; yet they are negative for PI. A nearly 
identical flow cytometric profile was obtained in a parallel staining 
study using a commercial annexin V staining kit, which is regarded as 
a gold standard for in vitro cell viability analysis (Figs. 1C and 1D).  
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Figure 1. Flow cytometry of control (A and C) and camptothecin-treated (B and D) 
Jurkat cells, with FITC-labeled C2A-GST (A and B) and annexin V (C and D) and 
costaining with PI and double staining using C2A-GST-AF680 and annexin V-FITC (E). 
Four distinct populations identified by C2A-GST-FITC are illustrated in B, including 
viable (V), early apoptotic (EA), apoptotic (A), and necrotic cells (N).  
To further evaluate the binding specificity of C2A-GST, double 
staining of camptothecin-treated Jurkat cells was performed with 
coincubation of C2A-GST-AF680 (red) and annexin V-FITC (green) and 
analyzed by dual-color flow cytometry. Simultaneous uptake of both 
red and green fluorescence was seen in each positive cell (Fig. 1E), 
whereas the viable cells were negative. There was clearly an absence 
of single positive cells for either color. The 2 fluorochromes were 
selected to minimize emission spectra overlap, where the emission 
wavelength of AF680 is near-infrared and FITC is in the green 
fluorescence range (Fig. 1E).  
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99mTc Labeling of C2A-GST  
According to Ellman's method, each molecule of C2A-GST 
contains an average of 2.87 and 7.15 thiols before and after 
iminothiolation, respectively. The radiochemical yield and purity data 
of the nonthiolated and thiolated C2A-GST are as follows: Before gel-
filtration purification, the RCP values for the native and thiolated 
protein are 12.5% and 72.8%, respectively. After gel-filtration 
purification, the values are 88.4% and 98.9%, respectively. Under 
identical labeling conditions, the radiochemical yield is enhanced ∼4-
fold with thiolation. The stability of the labeled protein was tested in 
saline, rat whole blood, and rat serum. The protein retained the 
radiolabel over a 24-h period as determined by ITLC (Table 1).  
TABLE 1 Stability Test for 99mTc-C2A-GST  
Fluid 0 h 1 h 2 h 4 h 24 h 
Saline 99.53 99.53 99.12 98.70 98.42 
Rat serum 99.53 96.42 95.70 93.40 91.32 
Rat whole blood 99.53 90.85 90.77 90.08 89.17 
 99mTc-C2A-GST was incubated with saline, rat serum, or whole blood for 1, 2, 
4, and 24 h. RCP was determined using ITLC.  
In Vitro Binding Assays 
The uptake and binding specificity of 99mTc-C2A-GST were 
evaluated using camptothecin-treated Jurkat cells as the binding 
target. For 5 × 105 cells after 3 h of stimulation and incubation with 
99mTc-C2A-GST, the radioactivity uptake was 9.12-fold ± 0.6 higher 
than that of the nontreated viable control population. In comparison, 
99mTc-C2A-GST-NHS showed a 1.88 ± 0.04 times difference under 
identical experimental conditions. In the presence of increasing 
concentrations of unlabeled C2A-GST, the uptake of radioactivity in 
treated Jurkat cells was competitively inhibited, with a well-defined 
sigmoid pattern. Using 5 × 105 treated cells and 80 nmol/L 99mTc-C2A-
GST, the IC50 of unlabeled C2A-GST was 90.01 ± 11.12 nmol/L (n = 
3). However, the competition profile was absent when unlabeled C2A-
GST was replaced with bovine serum albumin, GST, or C2A-GST-NHS.  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Nuclear Medicine, Vol. 47, No. 8 (August 2006): pg. 1367-1374. Publisher link. This article is © Society of 
Nuclear Medicine and Molecular Imaging and permission has been granted for this version to appear in e-
Publications@Marquette. Society of Nuclear Medicine and Molecular Imaging does not grant permission for this article to 
be further copied/distributed or hosted elsewhere without the express permission from Society of Nuclear Medicine and 
Molecular Imaging. 
13 
 
Biodistribution and Blood Clearance 
The distribution of radioactivity after intravenous injection of 
99mTc-C2A-GST in healthy rats is summarized as a function of time 
(Fig. 2). The most prominent organs of uptake include the liver and 
kidneys, suggesting hepatic and renal clearance. The presence of 
radioactivity in the spleen, bones, and lungs was significant, with the 
latter reflecting the blood-pool activity. In contrast, there is relatively 
low uptake in viable myocardium, gastrointestinal tract, adipose 
tissues, skeletal muscles, and skin. There is no indication that the 
radiotracer crosses the blood–brain barrier. A low thyroid uptake 
suggests that there was minimal dissociation of the radioisotope from 
the labeled protein. The blood clearance of 99mTc-C2A-GST was typical 
for a macromolecule of comparable size, with an estimated half-life of 
the fast clearance phase at <15 min (n = 5). No toxicity effect was 
observed at the current dosage.  
 
Figure 2. Biodistribution of 99mTc-C2A-GST in healthy rats at 10, 30, 60, and 180 min 
after injection (n = 5). Radioactivity uptake is shown in terms of %ID/g (A) 
and %ID/organ (B).  
 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Nuclear Medicine, Vol. 47, No. 8 (August 2006): pg. 1367-1374. Publisher link. This article is © Society of 
Nuclear Medicine and Molecular Imaging and permission has been granted for this version to appear in e-
Publications@Marquette. Society of Nuclear Medicine and Molecular Imaging does not grant permission for this article to 
be further copied/distributed or hosted elsewhere without the express permission from Society of Nuclear Medicine and 
Molecular Imaging. 
14 
 
Uptake Study in Rat Model of AMI 
The uptake of radioactivity in the area at risk versus normal 
myocardium after 99mTc-C2A-GST or 99mTc-C2A-GST-NHS injection in 
rats was quantified as a function of time using direct γ-counting. As 
summarized in Figure 3, the radioactivity level in the area at risk after 
99mTc-C2A-GST injection reached 1.91 ± 0.59 %ID/g within the first 10 
min after injection and plateaued between 2.40 and 2.63 %ID/g after 
30 min. The uptake in normal myocardium was 0.21 ± 0.01 %ID/g at 
10 min, with a gradual washout to 0.09 ± 0.04 %ID/g at 180 min. In 
comparison, radioactivity uptake from 99mTc-C2A-GST-NHS reached as 
high as 1.06 ± 0.49 %ID/g at 30 min, presumably due to nonspecific 
vascular leakage, followed by washout to 0.52 ± 0.23 %ID/g at 180 
min. The distribution of 99mTc-C2A-GST-NHS in normal myocardium 
over time was similar to that of 99mTc-C2A-GST. According to 
above %ID/g measurements, the target-to-background ratio between 
the area at risk and normal myocardium is 30.4 for 99mTc-C2A-GST, 
whereas the ratio is 6.5 for 99mTc-C2A-GST-NHS at 180 min after 
injection. TTC staining demonstrates the presence of infarct tissues 
within the area at risk, indicating the occurrence of extensive necrosis. 
This transition was in parallel with the elevation of apoptotic index 
from 0.27% to 4.70%. Short stimulation with 5 min of ischemia 
followed by reperfusion caused no significant uptake of 99mTc-C2A-GST 
in the area at risk compared with viable myocardium at 1 h after 
injection.  
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FIGURE 3. Radioactivity uptake, in terms of %ID/g, in rats in area at risk (AR) and in 
normal (VI) myocardium at 10, 30, 60, and 180 min after intravenous injection of 
99mTc-C2A-GST and 99mTc-C2A-GST-NHS (n = 4).  
In Vivo Imaging of AMI in Rat Model 
The biodistribution and uptake data were confirmed by in vivo 
planar imaging. Prominent hepatic uptake was seen in all cases 
immediately after radiotracer injection, followed by an increase in 
signal in the kidneys and bladder over time. As shown in Figure 4A, 
with the clearance of blood-pool and lung activities, a hot-spot uptake 
was visible as early as 40 min after injection, consistent with the 
location of the left anterior region of the left ventricle in infarct animals 
injected with 99mTc-C2A-GST. In 7 of 7 rats with an acute infarct, the 
signal became more focal and distinct over time. In contrast, neither 
infarct animals injected with 99mTc-C2A-GST-NHS nor sham-operated 
rats injected with 99mTc-C2A-GST showed significant tracer uptake in 
the left ventricle region (Fig. 4A). At 3 h after injection, the infarct-to-
lung ratios were 2.48 ± 0.27, 1.29 ± 0.09, and 1.46 ± 0.04 for acute 
infarct rats injected with 99mTc-C2A-GST (n = 7), sham-operated rats 
injected with 99mTc-C2A-GST (n = 3), and acute infarct rats injected 
with 99mTc-C2A-GST-NHS (n = 3), respectively. The presence of 
radioactivity in the area-at-risk region in rats injected with 99mTc-C2A-
GST was also confirmed by autoradiography and TTC staining (Fig. 
4B).  
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FIGURE 4. (A) In vivo single-photon planar imaging of sham-operated rat (Control) 
and rat with infarct at 0, 40, 80, 120, 160, and 200 min after intravenous injection of 
99mTc-C2A-GST. Arrow indicates site of the infarct. (B) Corresponding TTC staining and 
autoradiography images.  
Discussion 
This study evaluated a molecular probe, 99mTc-C2A-GST, and 
addressed the dynamic uptake profile using quantitative and 
semiquantitative methods in a rat model of reperfused AMI. The 
radiotracer targets PtdS as a common marker for both apoptosis and 
necrosis and detects cell death as a single comprehensive category.  
C2A-GST could be readily labeled with fluorochromes or a 
radioisotope. When fluorescently labeled, apoptosis and necrosis 
binding activity of the conjugates was comparable to that of annexin 
V. When coincubated with chemically treated cells in vitro, the 2 PtdS-
binding proteins associate with apoptotic and necrotic cells, suggesting 
that the 2 molecular probes interact with a shared molecular marker, 
presumably PtdS. C2A and annexin V are 2 structurally distinct 
proteins, whereas their binding activity is somewhat similar in that 
they interact with anionic phospholipids in a calcium-dependent 
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fashion16,31−35. In contrast to annexin family members that assume 
predominantly helical structures, C2A is a compact β-sandwich31–35. 
Given the importance of developing target-specific molecular probes 
for apoptosis and necrosis, a greater structural diversity should lead to 
a better chance of discovering isoforms or derivatives that generate 
favorable binding and pharmacokinetic properties. Although a direct 
and quantitative comparison between the 2 PtdS-binding proteins is 
beyond the scope of this study, it warrants further investigation in 
terms of binding activities, structural properties, and potentials for in 
vivo applications.  
For radiolabeling using 99mTc, thiolation of the fusion protein was 
essential, although there are native cysteine residues in native C2A-
GST. According to Ellman's method, the native protein contains an 
average of 2.87 thiols per molecule, whereas the conjugate has an 
average of 7.15. These data indicate that the conjugation introduced 
an average of 4.3 thiols per molecule. Although, according to 
sequencing there are 4 Cys residues in native C2A-GST, there appears 
to be a discrepancy between the measured and the actual number of 
thiol groups in the native protein (2.87 by Ellman's test vs. 4 from 
sequencing). This could be explained by the 3-dimensional structure of 
GST (EC 2.5.1.18; Schistosoma japonicum), where the side chain of 
Cys-169 is facing away from the protein surface while the thiol groups 
of Cys-85, Cys-138, and Cys-178 appear to be exposed and easily 
accessible. Thus, the outcome of Ellman's test could have reflected the 
orientation and accessibility of thiol groups to the colorimetric reagent, 
5,5′-dithio-bis-(2-nitrobenzoic acid), dissolved in the aqueous 
environment. The lack of efficient 99mTc incorporation before 
iminothiolation suggests that the endogenous thiols do not form 
favorable chelating sites for the radioisotope. The radiolabeled C2A-
GST has a relatively high RCP and good radiostability. After 
radiolabeling, 99mTc-C2A-GST appeared to have retained its binding 
activity. In vitro, significantly elevated uptake of the radiotracer was 
detected in camptothecin-treated Jurkat cells compared with that of 
the control. In addition, the fact that the binding of 99mTc-C2A-GST 
was reversible in the presence of competing unlabeled C2A-GST 
indicates that both forms of C2A-GST specifically interact with the 
same well-defined binding targets in treated cells and that the binding 
specificity of 99mTc-C2A-GST was well preserved.  
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Successful development of an infarct-avid imaging agent not 
only relies on an understanding of cell death processes but also is 
critically dependent on characterization of specific as well as passive 
distribution of such tracers. Vascular hyperpermeability associated 
with ischemic challenge have been well documented. This brings up 
the issue of diffusive leakage of a radiotracer into the interstitial space 
in parallel with specific uptake. To the best of our knowledge, the 
characterization of specific versus passive components has not been 
thoroughly documented to date. According to this study, accumulation 
of the inactivated tracer in the area at risk peaked at ∼30 min after 
injection and accounted for as much as 1 %ID/g, followed by a gradual 
washout. The data can be interpreted as extravasation of the tracer 
through compromised vascular structures and the diffusive distribution 
in interstitial space. During the initial period after injection, a high 
blood-pool concentration of the tracer favors infiltration into the area 
at risk. But with blood clearance, the shifting intravascular 
concentration drives the equilibrium toward a reversal and 
redistribution process as seen from the washout pattern. The timing 
and the degree of nonspecific uptake here are consistent with existing 
literature on ischemia- or reperfusion-induced vascular permeability 
changes measured using radiolabeled macromolecules and high-
molecular-weight MR contrast agents27,28. Although the binding of 
99mTc-C2A-GST-NHS with unknown targets in the area at risk could not 
be completely ruled out, such interactions, if any, are likely to be 
relatively weak and transient as the tracer is washed out with declining 
blood-pool activity. On the other hand, the active molecular probe, 
99mTc-C2A-GST, appears to be sequestered in the area at risk. This 
uptake of 99mTc-C2A-GST is likely to consist of both specific and 
nonspecific components. The fact that the uptake level plateaued after 
30 min may be a reflection of 2 dynamic components between a 
continuous accumulation due to specific binding and the vascular 
permeability-dependent diffusion equilibrium. The uptake of 99mTc-
C2A-GST positively correlates with ischemia or reperfusion challenge 
that results in infarction and elevation of apoptotic index in the area at 
risk, whereas short stimulation with 5 min of ischemia followed by 
reperfusion causes no significant uptake of 99mTc-C2A-GST in the area 
at risk.  
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The in vivo imaging results were consistent with ex vivo uptake 
studies and demonstrated the feasibility of noninvasive imaging of 
acute infarction in small-animal models. When calibrated against the 
marker, which represents 0.5 %ID, region-of-interest analysis 
indicates that the lesion uptake at the heart correlates with 0.7 to 
1 %ID. In healthy rats, 99mTc-C2A-GST clears from the blood pool in a 
well-defined profile. Meanwhile, the inactivated 99mTc-C2A-GST-NHS 
did not produce a target-to-background ratio that allows recognition of 
the infarct from the planar images.  
Conclusion 
With the synthesis and characterization of 99mTc-C2A-GST we 
describe the dynamic uptake of a PtdS-binding molecular probe in the 
area at risk. The data indicate that both specific binding and passive 
leakage due to vascular hyperpermeability contribute to the 
accumulation of the radiotracer at the area at risk. However, the latter 
component alone is insufficient to achieve detectable target-to-
background ratios with in vivo planar imaging. On the basis of this 
study, C2A and its derivatives hold promise in becoming suitable 
radiopharmaceuticals for the noninvasive imaging of apoptosis and 
necrosis.  
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